HC Wainwright Reaffirms Buy Rating for MindWalk (NASDAQ:HYFT)

MindWalk (NASDAQ:HYFT)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $5.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 304.86% from the stock’s previous close.

A number of other research firms have also recently issued reports on HYFT. Zacks Research upgraded MindWalk from a “strong sell” rating to a “hold” rating in a report on Monday, February 16th. UBS Group reissued a “buy” rating on shares of MindWalk in a research note on Friday, March 13th. Finally, JonesTrading started coverage on shares of MindWalk in a report on Thursday, April 16th. They issued a “buy” rating and a $5.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

MindWalk Stock Down 2.0%

MindWalk stock traded down $0.03 during trading hours on Tuesday, reaching $1.24. 76,511 shares of the company’s stock were exchanged, compared to its average volume of 400,359. The stock’s 50 day moving average price is $1.20. MindWalk has a twelve month low of $0.48 and a twelve month high of $3.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.74 and a quick ratio of 3.64. The firm has a market cap of $57.01 million, a price-to-earnings ratio of -6.18 and a beta of 0.65.

MindWalk (NASDAQ:HYFT) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). MindWalk had a negative net margin of 66.79% and a negative return on equity of 69.37%. The business had revenue of $3.00 million during the quarter, compared to analyst estimates of $3.50 million. Analysts anticipate that MindWalk will post -0.23 EPS for the current year.

Hedge Funds Weigh In On MindWalk

A number of large investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new position in MindWalk during the 4th quarter valued at about $51,000. Bridgeway Capital Management LLC purchased a new position in MindWalk during the fourth quarter worth about $91,000. Bank of Montreal Can boosted its stake in shares of MindWalk by 81.0% in the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after buying an additional 24,500 shares during the last quarter. XTX Topco Ltd grew its stake in MindWalk by 118.6% in the 4th quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock valued at $149,000 after purchasing an additional 44,331 shares during the period. Finally, Jane Street Group LLC increased its holdings in MindWalk by 147.3% during the fourth quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock worth $293,000 after buying an additional 96,018 shares during the last quarter. 6.70% of the stock is currently owned by institutional investors.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.